Subscribe
2020-09-21
21 September 2020AmericasMuireann Bolger

LSPN Connect: Challenges in the US patent landscape

Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda
22 October 2019   While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.
Americas
LSPN 19: Mayo has led us down the rabbit hole, says lawyer
26 April 2019   There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.
Biotechnology
LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101
28 October 2020   Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda
22 October 2019   While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.
Americas
LSPN 19: Mayo has led us down the rabbit hole, says lawyer
26 April 2019   There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.
Biotechnology
LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101
28 October 2020   Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.

More on this story

Americas
LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda
22 October 2019   While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.
Americas
LSPN 19: Mayo has led us down the rabbit hole, says lawyer
26 April 2019   There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.
Biotechnology
LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101
28 October 2020   Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent